Bausch Health Companies Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BHC in the last 30 days.
See all $BHC insider activity →Bausch + Lomb plans to begin clinical trials in 2027 for BL1243, an oral treatment for dry age-related macular degeneration (AMD). The FDA supported the initial study design, and Phase 2 advancement is expected if no unexpected findings occur. BL1243 aims to address a significant unmet need in early-stage dry AMD, with potential for a convenient, non-invasive treatment option.
Bausch + Lomb's Xiidra and Miebo combination therapy significantly improved dry eye symptoms in patients who had previously tried over four treatments. A study of 68 patients showed reduced dryness, improved staining, and better tear metrics. Most patients continued using both drops for about 194 days. Bausch + Lomb plans a phase 3 study for a combined drop.
Bausch Health (BHC) and YUN are expanding their probiotic skincare partnership into six new markets, including Mexico and Central/Eastern Europe. This follows BHC's raised full-year guidance after Q2 2026 revenue of $2.85B (+13% YoY) and EPS of $1.26 (+40% YoY). The International segment grew 10% (5% organic), while the Diversified segment, including Dermatology, remained flat.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BHC (Bausch Health Companies Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent BHC coverage spans technology, financial news and regulation.
The announcement may generate modest upside as investors price in a potential new product pipeline, but impact is limited until clinical data emerge.
Positive trial data may lift BHC as investors price in a potential new product.
The expansion signals revenue growth potential and increased international exposure.
Regulatory clearance may boost European sales and lift the stock as the product launches.
Modest decline mirrors health‑care sector lag.
AlphAI scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bausch + Lomb plans to begin clinical trials in 2027 for BL1243, an oral treatment for dry age-related macular degeneration (AMD). The FDA supported the initial study design, and Phase 2 advancement is expected if no unexpected findings occur. BL1243 aims to address a significant unmet need in early-stage dry AMD, with potential for a convenient, non-invasive treatment option.
1 min readBausch + Lomb's Xiidra and Miebo combination therapy significantly improved dry eye symptoms in patients who had previously tried over four treatments. A study of 68 patients showed reduced dryness, improved staining, and better tear metrics. Most patients continued using both drops for about 194 days. Bausch + Lomb plans a phase 3 study for a combined drop.
2 min readBausch Health (BHC) and YUN are expanding their probiotic skincare partnership into six new markets, including Mexico and Central/Eastern Europe. This follows BHC's raised full-year guidance after Q2 2026 revenue of $2.85B (+13% YoY) and EPS of $1.26 (+40% YoY). The International segment grew 10% (5% organic), while the Diversified segment, including Dermatology, remained flat.
2 min readBausch + Lomb received CE Mark approval for its SeeLyra femtosecond laser in Europe, allowing a limited rollout soon and broader availability in 2027. The laser is designed for cataract, LASIK, and corneal procedures, offering precision and flexibility. The company is also seeking approvals in other markets, including the U.S.
2 min readThe TSX rose 1.5% on Thursday, led by miners and tech, after Fed Governor Waller suggested patience on rate hikes. Celestica gained 11.4%, Wesdome Gold 8%, and Thomson Reuters 5%. The Canadian dollar strengthened to 72.53 cents. U.S. markets also climbed, with the Dow up 1.2%.
2 min readBausch + Lomb published real-world study results showing enVista Aspire IOLs provided good distance and intermediate vision post-cataract surgery. 100% of patients achieved binocular UIVA of 20/32 or better, with no serious adverse events. The study included 141 eyes, with 88 receiving enVista Aspire IOLs and 53 receiving enVista Aspire toric IOLs.
2 min readSight Sciences' TearCare System received FDA approval for treating meibomian gland dysfunction. Oculis began a registrational trial for Privosegtor in optic neuritis. Harrow reported positive results for IHEEZO in reducing discomfort post-injections. Bausch + Lomb will advance two treatments based on clinical results. Lupin licensed YUVEZZI for presbyopia treatment in Europe. Research showed antibiotic injections reduce endophthalmitis risk in cataract surgery.
3 min readBausch + Lomb announced phase 3 plans for a dual-action dry eye drop combining lifitegrast and PFHO, after phase 2 results showed a significant reduction in corneal staining at Day 15. The company also reported positive phase 1b data for BL1332, a TRPV1 antagonist eye drop, showing significant pain reduction in a capsaicin challenge model. Both treatments showed acceptable safety profiles. Phase 2 trials for BL1332 are ongoing.
2 min readBausch + Lomb will advance its dry eye treatment to Phase III despite mixed Phase II results. The eye drop, combining lifitegrast and perfluorohexyloctane, missed its primary endpoint but showed statistical significance in a secondary analysis. The company also progresses BL1332 to Phase II after positive pain reduction data in a Phase Ib trial.
2 min readBausch + Lomb will advance its dry eye drug to Phase III trials, focusing on day 15 results after missing day 29 goals. Its pain treatment, BL1332, met Phase Ib goals, reducing pain intensity and duration. The company plans to consult with the FDA.
1 min read
